Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children
Jennifer Whangbo(Boston Children's Hospital), John Koreth(Otsuka (Japan)), Leslie Lehmann(Harvard University), Jerome Ritz(Harvard University), Michelle A. Lee(Boston Children's Hospital), Nikola Mirkovic(Dana-Farber Cancer Institute), Kelly Verrill(Boston Children's Hospital), Samuel J. Poryanda(Dana-Farber Cancer Institute), Corey Cutler(Dana-Farber Cancer Institute), Vincent T. Ho(Dana-Farber Cancer Institute), Haesook T. Kim(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Joseph H. Antin(Texas Oncology), Bruce R. Blazar(University of Minnesota Medical Center), Robert J. Soiffer(Dana-Farber Cancer Institute), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Sophie Silverstein(Boston Children's Hospital), Lauren Leonard(Boston Children's Hospital), Soomin Kim(Dana-Farber Cancer Institute), Carol Reynolds(Harvard University), Christine Duncan(Dana-Farber Cancer Institute), Sarah Nikiforow(Otsuka (Japan)), Steven Margossian(Boston Children's Hospital), Jennifer T. Huang(Boston Children's Hospital)
Cited by 62
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|720
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664